DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 20-151/S-017/S-018
NDA 20-699/S-015/S-016

Wyeth-Ayerst Research
Attention: Kenneth R. Bonk
Associate Director, Worldwide Regulatory Affairs
P.O. BOX 8299
Philadelphia, PA, 19101-8299

Dear Mr. Bonk:

Please refer to your supplemental new drug applications dated May 5, 2000, May 18, 2000, and May 19, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Effexor Tablets and Effexor XR Capsules.

We acknowledge receipt of your submission dated March 19, 2001. Your submission of March 19, 2001 constituted a complete response to our February 28, 2001 action letter.

These supplemental new drug applications provide for the use of Effexor Tablets and Effexor XR Capsules for the prevention of recurrence of depression and for the prevention of relapse of depression.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling dated March 19, 2001.

Please submit the copies of final printed labeling (FPL) electronically to each application according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA* (January 1999). Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplement NDA 20-151/S-017, S-018, 20-699/S-015, S-016". Approval of these submissions by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42

Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Melaine Shin, R.Ph., Regulatory Management Officer, at (301) 594-5793.

Sincerely,

{See appended electronic signature page}

Russell Katz, M.D.
Director
Division of Neuropharmacological Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure